Consensus Shanghai Henlius Biotech, Inc. OTC Markets

Equities

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-.--%

Apr. 26	Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA	MT
Apr. 24	Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China	MT

6c.IRXZcLksEIe_hZPyZZxuK5qhgtsUl45ON_Ti2LIGgJs.cHGzAtxUSsqLsdKmUdoJW-zR4LRWyMsdT5qnoeAzy6tOZp0piWBEzNbaqw~de017a13b66f9170050cafcfd961efba

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

15.52 CNY

Average target price

16.39 CNY

Spread / Average Target

+5.58%

High Price Target

23.05 CNY

Spread / Highest target

+48.50%

Low Price Target

8.352 CNY

Spread / Lowest Target

-46.19%

Trading Rating

Investor Rating

ESG Refinitiv